NCT04387526View on ClinicalTrials.gov

Sofosbuvir Plus Daclatasvir With or Without Ribavirin and Chronic HCV Genotype (GT) 4

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

946

Participants

Timeline

Start Date

April 1, 2016

Primary Completion Date

May 31, 2017

Study Completion Date

May 31, 2017

Conditions
Chronic Hepatitis C Virus Infection
Interventions
DRUG

(SOF and DCV)

DRUG

(SOF, DCV, and RBV)

All Listed Sponsors
lead

Beni-Suef University

OTHER

NCT04387526 - Sofosbuvir Plus Daclatasvir With or Without Ribavirin and Chronic HCV Genotype (GT) 4 | Biotech Hunter | Biotech Hunter